The test failed!

CompileKe Ke

A few days ago, Novartis quietly revealed in its first quarter 2021 financial report that the Phase 3 clinical trial Paradise-MI showed that Entresto missed the primary endpoint of reducing the risk of cardiovascular death and heart failure after acute myocardial infarction.

In this study, the data of the trial results consistently support that Entresto has a better trend than the standard treatment ramipril, and Entresto has not reached its goal.

Novartis initiated the Paradise-MI clinical study in 2016 to see if Entresto can surpass the widely used ACE inhibitor ramipril in reducing cardiovascular death and heart failure in patients with heart attacks.

Although the results of the study are not satisfactory, in terms of sales, Entresto's sales in the first quarter increased by 39% to $789 million, helping Novartis to offset the problem of sales decline caused by competition in the generic drug business.

Entresto's trial failure occurred shortly after a major victory for the drug's heart failure indication.

In addition to Entresto's existing studies on patients with chronic heart failure and reduced ejection fraction, the approval also positions the drug as the first and only drug approved in both cases.

Peter Welford, an analyst at Jefferies, a well-known Wall Street investment bank, wrote in 2020 when an independent team of the US FDA supported the use of the drug in patients with HFpEF, that Entresto's maximum sales are expected to increase by another $1 billion.

In addition, Novartis’s first quarter 2021 financial report showed that net sales fell by 2% to 12.

Reference source:

1.

2.